论文部分内容阅读
目的化疗是晚期胃癌的主要治疗手段,晚期胃癌的化疗至今国际上没有公认的标准化疗方案。本研究旨在探讨替吉奥联合伊立替康治疗晚期胃癌的临床疗效和不良反应。方法收集2013年5月—2016年5月安徽医科大学第一附属医院肿瘤内科收治的24例符合入组条件的晚期胃癌患者,给予伊立替康静脉滴注联合口服替吉奥方案化疗,每个患者至少完成2个周期化疗,预计4~6个周期的治疗,2个周期评价疗效,对疗效及不良反应进行观察。临床疗效采用新的实体瘤疗效评价标准(RECIST)进行评价,毒副反应按照WHO抗癌药物毒性反映分度标准评定分级。应用SPSS 13.0统计软件进行统计分析,药物疗效分析应用χ~2检验。结果 24例均可评价疗效,其中完全缓解1例,部分缓解7例,病变稳定7例。有效率为33.3%,疾病控制率62.5%。常见的不良反应有恶心、呕吐、乏力、骨髓抑制、转氨酶升高、迟发性腹泻等。不良反应多为Ⅰ/Ⅱ度,Ⅲ/Ⅳ度不良反应主要是白细胞减少(12.5%)、中性粒细胞减少(16.7%)、血小板减少(4.2%)、血红蛋白降低(4.2%)和迟发性腹泻(8.3%)。结论替吉奥联合伊立替康治疗晚期胃癌可有效提高近期有效率及疾病控制率,不良反应可耐受,给药方式亦比较方便,值得临床进一步应用。
The purpose of chemotherapy is the main treatment of advanced gastric cancer, chemotherapy of advanced gastric cancer so far there is no internationally accepted standard chemotherapy. The purpose of this study was to explore the clinical efficacy and adverse reactions of TIGO combined with irinotecan in the treatment of advanced gastric cancer. Methods Twenty-four patients with advanced gastric cancer admitted to Department of Oncology, the First Affiliated Hospital of Anhui Medical University from May 2013 to May 2016 were enrolled in combination with irinotecan in combination with oral tiotropium chemotherapy Patients completed at least two cycles of chemotherapy, is expected to 4 to 6 cycles of treatment, 2 cycles evaluation of efficacy, efficacy and adverse reactions were observed. The clinical efficacy was evaluated by the RECIST (New Solid Tumor Evaluation Index), and the toxicity was classified according to WHO’s criteria for the classification of toxicity of anticancer drugs. SPSS 13.0 statistical software for statistical analysis, drug efficacy analysis using χ ~ 2 test. Results All the 24 cases could evaluate the curative effect, including 1 complete remission, 7 partial remission and 7 stable lesions. The effective rate was 33.3% and the disease control rate was 62.5%. Common adverse reactions are nausea, vomiting, fatigue, myelosuppression, elevated transaminases, delayed diarrhea and so on. Adverse reactions were mostly grade I / II. Grade III / IV adverse reactions were mainly leucopenia (12.5%), neutropenia (16.7%), thrombocytopenia (4.2%), hemoglobin (4.2% Diarrhea (8.3%). Conclusion TEGO combined with irinotecan in the treatment of advanced gastric cancer can effectively improve the recent efficiency and disease control rates, adverse reactions can be tolerated, the mode of administration is also more convenient and worth further clinical application.